BioSpace News Archive

Spago Nanomedical AB announced that the company has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis - a chronic, debilitating condition that affects up to 10 percent of women of reproductive age.

AMO Pharma Limited announced completion of patient enrollment in the company’s REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.

AlzeCure Pharma AB announced that the subscription period in the Company’s capital raising begins December 06 and runs until December 20, 2022.

Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for NARCAN® (naloxone HCI) Nasal Spray, as an over-the-counter (OTC) emergency treatment for known or suspected opioid overdose.

BioVie Inc. today announced encouraging data suggesting that NE3107 has an impact on improving patients’ DNA methylation profiles, potentially impacting biomakers of aging-related disease states.

Opthea Limited announce a podium talk will be presented at the annual FLORetina congress, taking place in Rome, Italy from December 8-11, 2022.

Healis Therapeutics is pleased to announce that it has been competitively selected to present at the Biotech Showcase taking place January 9-11, 2023 in San Francisco.

Poseida Therapeutics, Inc. today announced it will present early clinical results from its Phase 1 clinical trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its annual Research and Development Day in New York, NY on December 14, 2022, at 9:00 am ET.

According to Nova one advisor, the global Drug Discovery Services market size is expected to hit around USD 34.2 billion by 2030 from valued at USD 16.9 billion in 2021 and growing at a CAGR of 14.9% from 2022 to 2030.